Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00625768
Registration number
NCT00625768
Ethics application status
Date submitted
20/02/2008
Date registered
28/02/2008
Date last updated
25/08/2009
Titles & IDs
Public title
Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Query!
Scientific title
A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Query!
Secondary ID [1]
0
0
AS1409-101
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Renal Cell Carcinoma
0
0
Query!
Metastatic Malignant Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - AS1409
Treatment: Drugs: AS1409
Study drug
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Tumor assessment
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
6 weeks, response confirmed at 4 weeks
Query!
Primary outcome [2]
0
0
Biomarkers (interferon-? and IP-10 Interferon)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Various timepoints cycles 1-6, pre- and post-dose; then 1,4 and 12 weeks post last dose
Query!
Primary outcome [3]
0
0
Adverse event monitoring
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Various timepoints cycles 1-6, pre- and post-dose; then 1,4 and 12 weeks post last dose
Query!
Eligibility
Key inclusion criteria
- Be 18 years or older at the time of giving informed consent.
- Histologically confirmed diagnosis of renal cell carcinoma or malignant melanoma.
- If renal cell carcinoma, of clear cell or chromophilic/papillary type, with metastases
at any site (but excluding patients with single bony lesion only).
- If malignant melanoma, unresectable Stage III disease or Stage IV disease, with
metastases at any site (but excluding patients with single bony lesion only)
- Patients with clinically stable CNS metastases may enter who have been treated with
surgery or radiation and who do not require steroid therapy.
- ECOG performance status 0-2.
- Patients who have received prior systemic treatment for their malignancy with
chemotherapeutic or biological therapies may enter, provided treatment was completed
within 4 weeks of study entry.
- Patients who have received prior experimental therapy may enter, provided treatment
was completed within 12 weeks of study entry.
- Have adequate bone marrow function as evidenced by neutrophils >1.5 x109/L and
platelets >100 x109/L.
- Have adequate liver and kidney function, as shown by serum bilirubin =1.5x upper limit
of normal for the laboratory; ALT and AST both =2x upper limit of normal; and
creatinine =1.5x upper limit of normal.
- Have either evaluable or measurable disease (patients entering an ascending dosage
cohort) or measurable disease (patients entering the study after MTD is defined).
- Patients who have failed and or are ineligible for standard first line therapy (in
accordance with individual institutional practice)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients with any of the following will be excluded from the study:
- Patients at poor medical risk because of non-malignant systemic disease or active
infection.
- History of clinically significant autoimmune or predominantly Th1-driven clinical
disorders (such as rheumatoid arthritis, psoriasis, chronic inflammatory bowel
disease, for example), with the exception of autoimmune endocrinopathies now treated
with replacement therapy.
- Diabetic retinopathy.
- Substantive surgery within 4 weeks prior to study entry, or expectation of surgery
during the study period.
- Malignancy other than renal cell carcinoma or malignant melanoma within 5 years of
study entry, except for non-melanoma skin cancer and cervical intraepithelial
neoplasia treated definitively or other cancer from which the patient has been
disease-free for 5 years.
- Concurrent treatment with systemic steroids or with other immunosuppressive therapies.
- If female, pregnant or breastfeeding;
- Women of child bearing potential or sexually active males, unless (1) the patient (if
female, or the patient's partner, if male) is surgically sterile or (2) using adequate
contraception (defined as either IUD, oral or depot contraceptive, or barrier plus
spermicide) while receiving study treatment and for at least 6 months after
termination of treatment. Women must be post-menopausal for at least 2 years to be
considered of non-childbearing potential
- Any concurrent medical or psychological condition that would limit the ability of the
patient to provide informed consent or to comply with the obligations of the study.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2009
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
13
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Hamilton
Query!
Country [3]
0
0
United Kingdom
Query!
State/province [3]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Antisoma Research
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of
AS1409 in single and repeated doses.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00625768
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
James Spicer, MD
Query!
Address
0
0
Kings College School of Medicine
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00625768
Download to PDF